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Abstract The effect of insulin on protein kinase activity and 
plasma membrane translocation of the glucose transporter 
GLUT 4 has been studied in adipocytes permeabilized by 
Streptolysin-O. Insulin increased protein kinase activity, and 
this was completely inhibited by the PKC pseudosubstrate 
inhibitor peptide (PKC19-36). Insulin-mediated translocation 
of GLUT 4 was also inhibited by the PKC inhibitor peptide. Both 
these insulin effects were blocked by a PKCp neutralizing 
antibody. Our results are consistent with the hypothesis that 
insulin activates PKCp activity in adipocytes in situ, and that this 
PKC activation is a component of the system whereby insulin 
regulates translocation of GLUT 4 to the plasma membrane. 
© 1997 Federation of European Biochemical Societies. 
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1. Introduction 
The role of protein kinase C (PKC) in insulin signalling has 
been one of the most controversial problems in the field of 
insulin action in recent years (Reviews [1-3]). In early studies 
a role of protein kinase C (PKC) in insulin signalling was 
indicated since we and others demonstrated insulin stimula-
tion of PKC activity in physiologically relevant tissues, i.e. 
skeletal muscle [4,5] and adipocytes [6]. Moreover, insulin 
was found to induce translocation of several isoforms of 
PKC from cytosol to membrane [7,8]. In contrast, other in-
vestigators failed to observe an effect of insulin on PKC ac-
tivity in adipocytes [9] hepatocytes [10], BC3H-1 cells [11] or 
several fibroblast cell lines [12]. In the present investigation we 
have examined whether insulin has a direct effect on protein 
kinase activity in situ, using Streptolysin-O (SLO)-permeabi-
lized adipocytes to avoid extraction procedures and in vitro 
assay of PKC. As reported in studies of PKC-mediated phos-
phorylation of intracellular proteins [13] and PKC activity in 
T-lymphocytes [14], this technique employs internalization of 
peptides into the adipocytes during incubation. In the present 
study we have used as substrate a peptide identical with the 
58-72 C-terminal residues of the protein phospholemman 
(PLM), which has been shown to be a good substrate for 
PKC in vitro [15]. The specificity of the protein kinase activity 
responding to insulin has then been examined by use of the 
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synthetic PKC pseudosubstrate (PKC19-36) peptide, which is 
known as a highly specific inhibitor of PKC [16,17]. 
Insulin stimulation of glucose transport is primarily medi-
ated by translocation of the glucose transporter GLUT 4 from 
an intracellular membrane pool (ICM) to the plasma mem-
brane (PM) [18]. A role of PKC in insulin-stimulated GLUT 4 
translocation and glucose transport has been suggested since 
PKC activators like phorbol 12-myristate 13-acetate partly 
mimic the insulin effect on these processes [19-22], and inhib-
itors of PKC such as staurosporine, sangivamycin, polymyx-
ine B, sphingosine and H7 have been shown to inhibit insulin-
stimulated glucose transport both in muscle and adipose tissue 
[23-28]. However, these inhibitors lack the specificity required 
as PKC inhibitors compared with the highly specific peptide 
inhibitor used in the present study, which has been shown to 
inhibit glucose uptake in adipocytes [29]. We have therefore 
also examined whether insulin-stimulated GLUT 4 transloca-
tion can be observed in permeabilized adipocytes, and em-
ployed the peptide inhibitor to analyse whether PKC may 
be involved in this phenomenon. 
2. Materials and methods 
2.1. Materials 
[y-32P]ATP was from Amersham, Bucks., UK while protein A (125I) 
was from ICN, Pharmaceutics Inc., Irvine, CA, USA. Streptolysin-O 
(SLO) was from RBI, (Research Biochemicals International), Natick, 
MA, USA. Collagenase, leupeptin, ATP and reagents for lactic acid 
dehydrogenase (LDH) determination were from Sigma, St. Louis, 
MO, USA. Highly purified insulin was a gift from NOVO NOR-
DISK, Copenhagen, Denmark. Male Wistar rats (150-200 g body 
weight) were from M0llegaard, Copenhagen, Denmark. A synthetic 
peptide comprising the COOH-terminal amino acid residues 58-72 of 
phospholemman (PLM) [15] (GTFRSSIRRLSTRRR, in single letter 
code) was prepared at the Peptide Synthesis Facility, Forskningspar-
ken, University of Oslo, Norway. A PKC pseudosubstrate peptide 
(PKC19-36) (RFARKGALRQKNVHEVKN) [16] and a PKA inhib-
itor peptide, PKI [5-24] ('Walsh' inhibitor) were gifts from Dr. A. 
Czernik, The Rockefeller University, New York. Anti-PKCp mono-
clonal antibody (mAb) was from Transduction Laboratories, Affinity 
Research Products Ltd., Mamhead, Exeter, UK. Rabbit anti glucose 
transporter, insulin regulatable (GLUT 4, IRGT) was from East 
Acres Biologicals, Southbridge, MA, USA. 
2.2. Cell preparation 
Adipocytes were isolated from epididymal fat pads from 8-12 rats 
by the method of Rodbell [30]. Following dissection the fat pads were 
minced and incubated in 'extracellular' buffer containing 129 mM 
NaCl, 5 mM KC1, 1.2 mM MgCl2, 1.3 mM CaCl2, 1.2 mM KH2P04 
with 20 mM HEPES (pH 7.4) containing 2 mM Na-pyruvate and 2% 
(w/v) BSA. Collagenase was added and incubation continued for 
90 min at 37°C. The cells were filtered through nylon screen and 
0014-5793/97/S17.00 © 1997 Federation of European Biochemical Societies. All rights reserved. 
P / /S0014-5793(97)00898-3 
O. Walaas et allFEBS Letters 413 (1997) 152-156 153 
washed 4 times by flotation and resuspension in 'extracellular' buffer. 
The cells were then washed once in 'intracellular' buffer containing 
120 mM KC1, 4 mM NaCl, 10 mM MgCl2, 1.2 mM KH2P04, 
1.25 mM CaCl2, 1 mM EGTA, leupeptin (10 Ug/ml), 20 mM HEPES 
buffer (pH 7.4), 2 mM Na-pyruvate and 2% BSA, resuspended in 
'intracellular' buffer, and aliquots were removed for incubation with 
SLO (2 U/ml). In preliminary experiments LDH was rapidly released 
from the permeabilized adipocytes by this treatment, and after 30 s 
incubation at 37°C, extracellular LDH approached the level seen fol-
lowing detergent treatment of cells with 1% Triton-X-100 (not 
shown). 
2.3. Determination of protein kinase activity 
The assay was done essentially as described by Alexander et al. [14]. 
Washed cell suspensions (185 ul) m 'intracellular' buffer were incu-
bated with 2 U/ml SLO at 37°C in plastic vials containing (final 
cone): 250 uM peptide substrate, 800 uM [y-32P]ATP, 10 mM MgCl2, 
without or with 1^10 uM PKC19-36 pseudosubstrate peptide inhib-
itor, and 20 mM HEPES, (pH 7.4) in the absence or presence of 
100 nM insulin in a total volume of 300 u l Reactions were terminated 
after the times indicated by addition of 120 ul 25% (w/v) trichloro-
acetic acid in 2 M acetic acid. Following centrifugation for 10 min, 
aliquots (30 ul) of the supernatants were spotted on P81 phosphocel-
lulose chromatography paper (Whatman), the papers were washed 
three times in 30% (v/v) acetic acid containing 1% (v/v) phosphoric 
acid for 30 min, and once in methanol, and radioactivity of the paper 
squares were determined by Cerenkov counting. Tubes containing no 
peptide substrate were included in the experiments to estimate 'back 
ground' phosphorylation. 
2.4. Determination of translocation of the insulin-regulated glucose 
transporter GLUT 4 
Washed cell suspensions were suspended in 'intracellular' buffer 
containing SLO (2 Unit/ml), 2 mM Na-pyruvate, 200 nM adenosine, 
5 mM ATP and leupeptin (10 ug/ml). Incubation was done at 37°C 
for 10 min in plastic vials in the absence or presence of 100 nM insulin 
and with addition of various concentrations of PKC pseudosubstrate 
peptide (19-36) or antibodies against PKCp as reported in the text. 
Following notation by centrifugation, the cells were washed once in 
homogenization buffer containing 250 mM sucrose, 10 mM NaF, 
10 mM Na-pyrophosphate, leupeptin (10 ug/ml) in 25 mM Tris-HCl 
buffer, (pH 7.4), suspended in the same buffer, and subcellular frac-
tionation done by the method of Karnieli et al. [31] to prepare plasma 
membranes (PM) and total intracellular membranes (ICM). The frac-
tions were suspended in 3% (w/v) SDS 'stop' solution, boiled for 
2 min, and after protein determination using color reagent from Pierce 
Chemical Co., aliquots containing 50 u,g protein were subjected to 
SDS-PAGE. Proteins were blotted on to polyvinylidene difluoride 
(PVDF) membranes, and immunoblotting analysis was done with 
antibodies raised against the C-terminal peptide of GLUT 4. Relative 
amounts of GLUT 4 were revealed by using protein A (125I) and 
quantification by excising appropriate bands followed by y-radiation 
counting. 
3. Results 
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Fig. 1. Insulin stimulates protein kinase activity in SLO-permeabi-
lized adipocytes. (A) PKC was identified in SLO-permeabilized adi-
pocytes by Western immunoblotting with a monoclonal PKCp neu-
tralizing antibody as a 80-kDa band. Following incubation of the 
adipocytes in the absence and the presence of insulin, a lOOOOOXg 
membrane pellet was solubilized in SDS, subjected to SDS-PAGE 
and transferred to PVDE blot as described in Section 2. (B) Insulin 
stimulates PLM-peptide phosphorylation in SLO-permeabilized adi-
pocytes in a concentration-dependent manner. Assays were per-
formed following 5 min incubation at 37°C without - o - or with 
- • - 100 nM insulin. (C) Time course of PLM-peptide phospho-
rylation in the absence - o - or the presence - • - of 100 nM insu-
lin at 250 uM PLM-peptide concentration. The details are described 
in Section 2. 
3.1. Protein kinase activity 
Following incubation of SLO-permeabilized adipocytes in 
the absence or presence of insulin, PKCp was identified in a 
lOOOOOXg membrane fraction by Western immunoblotting 
with a PKCp monoclonal antibody as an 80-kDa band, the 
amount of which was increased after incubation of the cells 
with insulin (Fig. 1A). SLO-treated adipocytes were also able 
to catalyze phosphorylation of the PLM-peptide under basal 
conditions, and the extent of this phosphorylation was in-
creased following incubation with insulin (Fig. IB). Following 
a lag period of about 2 min, which may be attributed to 
activation of the insulin signalling cascade pathway, this effect 
of insulin was seen during 2-10 min incubation, and repre-
sented an 1-3-fold increase in PLM-peptide phosphorylation 
above control (Fig. 1C). Insulin is known to stimulate the 
activity of a series of serine/threonine kinases [32,33] and in 
order to detect whether a putative insulin-stimulated PKC was 
responsible, the PKC-specific peptide inhibitor was employed. 
When the PKC (19-36) peptide was included in the assay at a 
concentration of 40 U.M the level of phosphorylation induced 
by insulin was reduced to control level and there was also a 
partial inhibition of the control level of PLM peptide phos-
phorylation (Fig. 2A), in agreement with the presence of PKC 
in the control membrane as shown in Fig. 1A. The inhibition 
of the insulin-stimulated PLM peptide phosphorylation was 
concentration-dependent, with an apparent IC50 of 5 |J,M 
PKC (19-36) peptide (Fig. 2B). Moreover, a monoclonal 
PKCp neutralizing antibody present during incubation 
blocked insulin-stimulation of PLM-peptide phosphorylation 
(Fig. 2C). These results strongly indicate that the stimulation 
154 O. Walaas et al.lFEBS Letters 413 (1997) 152-156 
of PLM peptide phosphorylation by insulin solely is mediated 
by activation of PKC in adipocytes in situ. 
3.2. GLUT 4 translocation 
In accordance with previous work [34] the biochemical sys-
tem mediating insulin regulation of GLUT 4 translocation 
was found to be retained in SLO-permeabilized adipocytes. 
In the presence of insulin the content of GLUT 4 was in-
creased by 3^1 fold in PM, and decreased by 30% in ICM 
Insulin 
PKC (19-36) 
Plasma membranes 
Insulin - + - + 
PKC (19-36) - - + + 
Intracellular membranes 
- + - + 
- - + + 
B Blot: Anti-Glut4 
» > # « 
4 
B 
Insulin 
mAB-PKC, 
PKC (19-36), uM 
Fig. 2. The PKC-peptide (19-36) and a monoclonal PKCp neutraliz-
ing antibody inhibit insulin-stimulated PLM-peptide phosphoryl-
ation in SLO-permeabilized adipocytes. (A) The PKC-peptide (19-
36) at a concentration of 20 u,M inhibits insulin-stimulated PLM-
peptide phosphorylation. Assays carried out following 10 min incu-
bation at 37°C and with 250 uM PLM-peptide concentration 
(N=5). (B) PKC-peptide (19-36) inhibits insulin-stimulated PLM-
peptide phosphorylation in a concentration-dependent manner. Incu-
bation without - o - or with - • - insulin. The data are represen-
tative of four individual experiments with similar results. (C) A 
monoclonal PKCp neutralizing antibody at a concentration of 5 ug/ 
ml blocked insulin-stimulated PLM-phosphorylation (TV =4). 
P 
+ 
+ 
Fig. 3. Insulin-mediated translocation of GLUT 4 from ICM to PM 
is inhibited by PKC-peptide (19-36) and by a monoclonal PKCp 
neutralizing antibody. (A) SLO-permeabilized adipocytes were incu-
bated for 10 min at 37°C in the absence or the presence of 100 nM 
insulin, and GLUT 4 in PM and ICM isolated as described in Sec-
tion 2. In the presence of 20 uM PKC-peptide (19-36) insulin-medi-
ated translocation of GLUT 4 was blocked. (B) SLO-permeabilized 
adipocytes were incubated in the absence or the presence of insulin, 
and without or with monoclonal PKCp neutralizing antibody (5 [ig/ 
ml) for 10 min. GLUT 4 in PM was isolated and blotted on to 
PVDF membranes as described in Section 2. 
(Fig. 3A). This insulin-induced GLUT 4 translocation was 
completely prevented in the presence of 40 uJVI PKC (19-36) 
peptide. The specificity of this inhibitory effect was confirmed 
since 40 uM of the PKA inhibitor peptide PKI [5-24] had no 
effect (not shown). Inhibition of the insulin mediated increase 
of GLUT 4 in PM by the PKC inhibitor peptide was concen-
tration-dependent with an apparent IC50 of 2 U.M (Fig. 4). 
Similarly, the insulin mediated decrease in GLUT 4 in ICM 
was inhibited at an apparent IC50 concentration of 4 uM (Fig. 
5). These results strongly indicate that PKC is involved in the 
insulin signalling system for stimulation of GLUT 4 translo-
cation. Further support for this statement was obtained since 
the insulin-mediated translocation of GLUT 4 was strongly 
inhibited by a monoclonal PKCp neutralizing antibody (Fig. 
3B). 
4. Discussion 
The involvement of PKC in mediating insulin effects has 
remained a controversial problem for several years. Such 
problems may partly be caused by techniques used for extrac-
tion of membrane and cytosolic fractions followed by in vitro 
determination of PKC activity. The PKC enzyme family con-
tains in the Q domain an autoinhibitory pseudosubstrate 
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sequence which keeps the enzyme in the inactive form [35], 
and which is removed by the lipid PKC activators phospha-
tidylserine and diacylglycerol [36]. Extraction conditions com-
prising detergent treatment and chromatography might there-
fore affect both partition of PKC in membranes and cytosol 
and the basal state of activity, and in vitro determination of 
PKC activity may therefore not necessarily reflect true PKC 
activity in situ in the cell. The cell permeabilization technique 
used in the present investigation, and which allows measure-
ment of the activity of membrane-stabilized PKC in situ by 
internalization of specific substrates and inhibitors, appears to 
eliminate these problems. 
Our study shows that adipocytes contain an insulin-stimu-
lated protein kinase which phosphorylates a PLM-peptide 
which is known as a good substrate for PKC in vitro [15]. 
The phosphorylation of this PLM-peptide was blocked by the 
PKC pseudosubstrate peptide (PKC19-36). This compound is 
known as a highly specific inhibitor of PKC, with inhibition 
of phosphorylation of a peptide derived from glycogen syn-
thase occurring at an IC50 concentration of 0.2 u,M [16], and 
with inhibition of PKC activity in cytosolic cell extracts in 
vitro occurring at an apparent IC50 concentration of 1 uM, 
while other protein kinases were not inhibited at concentra-
tions below 1 mM [17]. In our study the insulin-stimulated 
PLM-peptide phosphorylation was inhibited by the PKC in-
hibitor peptide at concentrations comparable with inhibition 
of PKC activity in cytosolic cell extracts in vitro, displaying 
an apparent IC50 concentration of 5 uM. Hence, our results 
strongly indicates that adipocytes contain an insulin-sensitive 
A Blot: Anti-Glut4 
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Fig. 4. Concentration-dependent inhibition of insulin-mediated in-
crease of GLUT 4 in PM in SLO-permeabilized adipocytes by 
PKC-peptide (19-36). SLO-permeabilized adipocytes were incubated 
as described in Fig. 3A and GLUT 4 in PM isolated as described in 
Section 2. The GLUT 4 bands on the autoradiogram (A) were cut 
out and quantitated by y-radiation counting (B). The data are repre-
sentative of four individual experiments with similar results. The 
125I radioactivity incorporated into the GLUT 4 band was 245 cpm 
(control) and 808 cpm (insulin). 
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B 
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Fig. 5. Concentration-dependent inhibition of insulin-mediated de-
crease of GLUT 4 in ICM in SLO-permeabilized adipocytes by 
PKC-peptide (19-36). Following incubation as described in Fig. 3, 
GLUT 4 in ICM was isolated as described in Section 2. The GLUT 
4 bands on the autoradiogram (A) were cut out and quantitated by 
y-radiation counting (B). The data are representative of three indi-
vidual experiments with similar results. The 125I radioactivity incor-
porated into the GLUT 4 band was 533 cpm (control) and 263 cpm 
(insulin). 
PKC and that this enzyme can phosphorylate PKC-substrates 
in situ. This is in agreement with our previous work on intact 
muscle where insulin increased phosphorylation of phospho-
lemman at serine-63 and serine-68, both sites phosphorylated 
by PKC in vitro [37,15]. 
Previous studies have shown that vesicle-mediated translo-
cation of GLUT 4 to PM persists in permeabilized adipocytes. 
Insulin stimulated GLUT 4 translocation in oc-toxin treated 
adipocytes [38], and in SLO-permeabilized 3T3-L1 adipocytes 
insulin-mediated GLUT 4 translocation was seen if a source 
of ATP was added [34]. This was confirmed in our work on 
SLO-permeabilized adipocytes, with 3^1-fold increase of insu-
lin-stimulated GLUT 4 translocation to PM, determined by 
differential centrifugation method [31]. Recent studies indicate 
that phosphatidyl-inositol-3-kinase is of central importance in 
the GLUT 4 vesicle translocation process [39-41]. Other stud-
ies have shown that in addition to a phosphatidylinositol-3-
kinase (Vps34) a serine protein kinase (Vpsl5) is an essential 
component in regulating transmembrane protein sorting in 
yeast [42]. Therefore, we have investigated if protein kinase 
activity also may be involved in GLUT 4 translocation in 
adipocytes. Our work demonstrates that insulin-mediated 
translocation of GLUT 4 from an ICM pool to PM can be 
seen in the permeabilized adipocytes, and that this effect is 
inhibited by the PKC pseudosubstrate inhibitor at similar 
concentration levels as shown for inhibition of insulin stimu-
lated PKC activity in the adipocytes. The specificity of the 
effect of the PKC-peptide (19-36) inhibitor was confirmed 
since a PKI inhibitor peptide (5-24) had no effect on insulin 
stimulation of protein kinase activity or GLUT 4 transloca-
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tion (not shown). Moreover, the insulin-stimulation of protein 
kinase activity as well as the insulin-mediated G L U T 4 trans-
location was blocked by a PKCp neutralizing monoclonal 
antibody. These results indicate a requirement for insulin 
stimulation of P K C activity in the insulin signalling pathway 
of translocation of G L U T 4. In conclusion, our work are 
consistent with the hypothesis that insulin can stimulate 
P K C activity in adipocytes in situ, and that this activation 
of P K C is a component in the regulation of G L U T 4 vesicle 
translocation which occurs in response to insulin. 
Acknowledgements: We thank Dr. A. Czernik for a gift of peptide 
inhibitors and NOVO NORDIC for a gift of insulin. We are indebted 
to Ellen Martinsen for typing the manuscript. 
References 
Grunberger, G. (1991) Cell. Signal. 3, 171-177. 
Farese, R.V., Standaert, M.L., Arnold, T., Yu, B., Ishizuka, T., 
Hoffman, J., Vila, M. and Cooper, D.R. (1992) Cell. Signal. 4, 
133-143. 
Considine, R.V. and Caro, J.F. (1993) J. Cell. Biochem. 52, 8-13. 
Walaas, S.I., Horn, R.S., Adler, A., Albert, K.A. and Walaas, O. 
(1987) FEBS Lett. 220, 311-318. 
Cooper, D.R., Konda, T.S., Standaert, M.L., Davis, J.S., Pollet, 
R.J. and Farese, R.V. (1987) J. Biol. Chem. 262, 3633-3639. 
Egan, J.J., Saltis, J., Wek, S.A., Simpson, I.A. and Londos, C. 
(1990) Proc. Natl. Acad. Sci. USA 87, 1052-1056. 
Walaas, O., Parker, P., Horn, R. and Walaas, I. (1992) Acta 
Endocrinol. 126, suppl. 3, 11. 
Yamada, K., Avignon, A., Standaert, M.L., Cooper, D.R., 
Spencer, B. and Farese, R.V. (1995) Biochem. J. 308, 177-180. 
Glynn, B.P., Colliton, J.W., McDermott, J.M. and Witters, L.A. 
(1986) Biochem. Biophys. Res. Commun. 135, 1119-1125. 
Vaartjes, W.J., de Haas, C.G.M., Chang, K., Sherman, W.R. and 
Turk, J. (1986) Biochem. Biophys. Res. Commun. 138, 1328-
1333. 
Spach, D.H., Nemenoff, R.A. and Blackshear, P.J. (1986) J. Biol. 
Chem. 261, 12750-12753. 
Blackshear, P.J., Haupt, D.M. and Stumpo, D.J. (1991) J. Biol. 
Chem. 266, 10946-10952. 
Alexander, D.R., Hexham, J.M., Lucas, S.C., Graves, J.D., Can-
trell, D.A. and Crumpton, M.J. (1989) Biochem. J. 260, 893-901. 
Alexander, D.R., Graves, J.D., Lucas, S.C., Cantrell, D.A. and 
Crumpton, M.J. (1990) Biochem. J. 268, 303-308. 
Walaas, S.I., Czermk, A.J., Olstad, O.K., Sletten, K. and Walaas, 
O. (1994) Biochem. J. 304, 635-640. 
House, C. and Kemp, B.E. (1987) Science 238, 1726-1728. 
[17] Meier, K.E., Licciardi, K.A., Haystead, T.A. and Krebs, E.G. 
(1991) J. Biol. Chem. 266, 1914-1920. 
[18] Holman, G.D. and Cushman, S.W. (1994) Bioessays 16, 753-759. 
[19] Muhlbacher, C , Karnieli, E., Schaff, P., Obermaier, B., 
Mushack, J., Rattenhuber, E. and Haring, H.U. (1988) Bio-
chem. J. 249, 865-870. 
[20] Vogt, B., Mushack, J., Seffer, E. and Haring, H.U. (1991) Bio-
chem. J. 275, 597-600. 
[21] Gibbs, E.M., Calderhead, D.M., Holman, G.D. and Gould, 
G.W. (1991) Biochem. J. 275, 145-150. 
[22] Saltis, J., Habberfield, A.D., Egan, J.J., Londos, C , Simpson, 
I.A. and Cushman, S.W. (1991) J. Biol. Chem. 266, 261-267. 
[23] Holman, G.D., Kozka, I.J., Clark, A.E., Flower, C.J., Saltis, J., 
Habberfield, A.D., Simpson, I.A. and Cushman, S.W. (1990) 
J. Biol. Chem. 265, 1872-1879. 
[24] Robertson, D.G., DiGirolamo, M., Merrill Jr., A.H. and Lam-
beth, J.D. (1989) J. Biol. Chem. 264, 6773-6779. 
[25] Standaert, M.L., Buckley, D.J., Ishizuka, T., Hoffman, J.M., 
Cooper, D.R., Pollet, R.J. and Farese, R.V. (1990) Metabolism 
39, 1170-1179. 
[26] Tanti, J.F., Rochet, N., Gremeaux, T., Van Obberghen, E. and 
Le Marchand-Brustel, Y. (1989) Biochem. J. 258, 141-146. 
[27] Christensen, R.L., Shade, D.L., Graves, C.B. and McDonald, 
J.M. (1987) Int. J. Biochem. 19, 259-265. 
[28] Nishimura, H. and Simpson, I.A. (1994) Biochem. J. 302, 271-
277. 
[29] Standaert, M.L., Sasse, J., Cooper, D.R. and Farese, R.V. (1991) 
FEBS Lett. 282, 139-142. 
[30] Rodbell, M. (1964) J. Biol. Chem. 239, 375-380. 
[31] Karnieli, E., Zarnowski, M.J., Hissin, P.J., Simpson, I.H., Salans, 
L.B. and Cushman, S.W. (1981) J. Biol. Chem. 256, A112-A111. 
[32] Czech, M.P., Klarlund, J.K., Yagaloff, K.A., Bradford, A.P. and 
Lewis, R.E. (1988) J. Biol. Chem. 263, 11017-11020. 
[33] Walaas, O., Walaas, E., Lystad, F., Alertsen, Aa.R. and Horn, 
R.S. (1979) Mol. Cell. Endocrinol. 16, 45-55. 
[34] Robinson, L.J., Pang, S., Harris, D.S., Heuser, J. and James, 
D.E. (1992) J. Cell. Biol. 117, 1181-1196. 
[35] Newton, A.C. (1995) J. Biol. Chem. 270, 28495-28498. 
[36] Orr, J.W., Keranen, L.M. and Newton, A.C. (1992) J. Biol. 
Chem. 267, 15263-15266. 
[37] Walaas, O., Horn, R.S. and Walaas, S.I. (1991) Biochim. Bio-
phys. Acta 1094, 92-102. 
[38] Baldini, G., Hohman, R., Charron, M.J. and Lodish, H.F. (1990) 
J. Biol. Chem. 266, 4037^1040. 
[39] Cheatham, B., Vlahos, C , Cheatham, L., Wang, L., Blenis, J. 
and Kahn, C.R. (1994) Mol. Cell. Biol. 14, 4902-4911. 
[40] Okada, T., Kawano, Y., Sakakibara, T., Hazeki, O. and Ui, M. 
(1994) J. Biol. Chem. 269, 3568-3573. 
[41] Heller-Harrison, R.A., Morin, M., Guilherme, A. and Czech, 
M.P. (1996) J. Biol. Chem. 271, 10200-10204. 
[42] Stack, J.H., Herman, P.K., Schu, P.V. and Emr, S.D. (1993) 
EMBO J. 12, 2195-2204. 
